A new working group at the Federal Trade Commission is seeking public input on the commission’s reviews of drug industry mergers, which are becoming more common and have raised concerns about anticompetitive conduct. “Public input is critical to the process of refreshing our approach to pharmaceutical mergers,” said FTC Acting Chair Rebecca Slaughter. “In the face of skyrocketing drug prices and ongoing concerns about anticompetitive conduct by pharmaceutical companies, we need to ensure that our investigations fully capture the potential...